PL1818329T3 - Dihydrat chlorowodorku (S)-(-)-1-(4-fluoroizochinolin-5-ylo)sulfonylo-2-metylo-1,4-homopiperazyny - Google Patents

Dihydrat chlorowodorku (S)-(-)-1-(4-fluoroizochinolin-5-ylo)sulfonylo-2-metylo-1,4-homopiperazyny

Info

Publication number
PL1818329T3
PL1818329T3 PL05811715T PL05811715T PL1818329T3 PL 1818329 T3 PL1818329 T3 PL 1818329T3 PL 05811715 T PL05811715 T PL 05811715T PL 05811715 T PL05811715 T PL 05811715T PL 1818329 T3 PL1818329 T3 PL 1818329T3
Authority
PL
Poland
Prior art keywords
fluoroisoquinolin
sulfonyl
dihydrate
2methyl
hydrochloride dihydrate
Prior art date
Application number
PL05811715T
Other languages
English (en)
Inventor
Takeshi Ohshima
Hiroyoshi Hidaka
Masami Shiratsuchi
Kazuhiro Onogi
Toshiaki Oda
Original Assignee
Kowa Co
D Western Therapeutics Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1818329(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Co, D Western Therapeutics Inst Inc filed Critical Kowa Co
Publication of PL1818329T3 publication Critical patent/PL1818329T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL05811715T 2004-11-29 2005-11-29 Dihydrat chlorowodorku (S)-(-)-1-(4-fluoroizochinolin-5-ylo)sulfonylo-2-metylo-1,4-homopiperazyny PL1818329T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004344271 2004-11-29
PCT/JP2005/021844 WO2006057397A1 (ja) 2004-11-29 2005-11-29 （ｓ）－（－）－１－（４－フルオロイソキノリン－５－イル）スルホニル－２－メチル－１，４－ホモピペラジン塩酸塩・二水和物
EP05811715A EP1818329B1 (en) 2004-11-29 2005-11-29 (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2methyl-1,4homopiperazine hydrochloride dihydrate

Publications (1)

Publication Number Publication Date
PL1818329T3 true PL1818329T3 (pl) 2010-10-29

Family

ID=36498130

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05811715T PL1818329T3 (pl) 2004-11-29 2005-11-29 Dihydrat chlorowodorku (S)-(-)-1-(4-fluoroizochinolin-5-ylo)sulfonylo-2-metylo-1,4-homopiperazyny

Country Status (23)

Country Link
US (1) US7858615B2 (pl)
EP (1) EP1818329B1 (pl)
JP (1) JP4016060B2 (pl)
KR (1) KR101253369B1 (pl)
CN (1) CN101068806B (pl)
AT (1) ATE465159T1 (pl)
AU (1) AU2005308060B2 (pl)
BR (1) BRPI0517909B8 (pl)
CA (1) CA2589237C (pl)
CY (1) CY1112406T1 (pl)
DE (1) DE602005020835D1 (pl)
DK (1) DK1818329T3 (pl)
EA (1) EA011283B1 (pl)
ES (1) ES2345562T3 (pl)
MX (1) MX2007006322A (pl)
MY (1) MY139797A (pl)
NO (1) NO339021B1 (pl)
NZ (1) NZ555560A (pl)
PL (1) PL1818329T3 (pl)
PT (1) PT1818329E (pl)
TW (1) TWI354670B (pl)
WO (1) WO2006057397A1 (pl)
ZA (1) ZA200704201B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290827A (ja) * 2005-04-13 2006-10-26 Kowa Co 緑内障予防又は治療剤
CA2621181C (en) * 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
US8415372B2 (en) * 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2012026529A1 (ja) 2010-08-26 2012-03-01 興和株式会社 イソキノリン誘導体又はその塩の新規製造方法
JP5557408B1 (ja) * 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
PL3199161T3 (pl) * 2014-09-25 2022-04-11 Kowa Company, Ltd. Preparat farmaceutyczny
US10369781B2 (en) * 2015-01-08 2019-08-06 Hewlett-Packard Development Company, L.P. Mobile printers
CN107216311B (zh) * 2016-03-21 2019-09-03 山东诚创医药技术开发有限公司 (s)-4-[(4-氟代异喹啉-5-基)磺酰基]-3-甲基-1,4-二氮杂环庚烷盐酸盐的精制方法
CN106496189A (zh) * 2016-10-10 2017-03-15 江苏礼华生物技术有限公司 盐酸Ripasudil晶型
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
CA3120751A1 (en) 2018-12-17 2020-06-25 D. Western Therapeutics Institute, Inc. New form of isoquinoline sulfonamide
JP7398137B2 (ja) 2019-06-21 2023-12-14 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド Ｒｏｃｋプロテインキナーゼ阻害薬としてのイソキノリンの誘導体及びその使用
CN114644618A (zh) * 2020-12-21 2022-06-21 广州润尔眼科生物科技有限公司 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734531B2 (ja) 1995-06-29 2006-01-11 旭化成ファーマ株式会社 １−（５−イソキノリンスルホニル）ホモピペラジン塩酸塩３水和物
CN1080721C (zh) 1995-07-03 2002-03-13 旭化成株式会社 1－(5－异喹啉磺酰基)高哌嗪盐酸盐水合物
ES2205166T3 (es) * 1996-02-02 2004-05-01 D. Western Therapeutics Institute Derivados de isoquinolina y medicamento.
AU9646198A (en) * 1997-10-22 1999-05-10 Nippon Shinyaku Co. Ltd. Isoquinoline derivative and drug

Also Published As

Publication number Publication date
EP1818329B1 (en) 2010-04-21
MY139797A (en) 2009-10-30
JP4016060B2 (ja) 2007-12-05
KR101253369B1 (ko) 2013-04-11
ATE465159T1 (de) 2010-05-15
ZA200704201B (en) 2008-09-25
AU2005308060B2 (en) 2011-02-17
NZ555560A (en) 2008-10-31
EP1818329A4 (en) 2009-08-05
WO2006057397A1 (ja) 2006-06-01
BRPI0517909B1 (pt) 2018-11-21
PT1818329E (pt) 2010-06-22
KR20070084127A (ko) 2007-08-24
BRPI0517909B8 (pt) 2021-05-25
DK1818329T3 (da) 2010-07-19
DE602005020835D1 (de) 2010-06-02
CN101068806B (zh) 2012-02-01
BRPI0517909A (pt) 2008-10-21
AU2005308060A1 (en) 2006-06-01
HK1112898A1 (en) 2008-09-19
US20080021018A1 (en) 2008-01-24
ES2345562T3 (es) 2010-09-27
EA011283B1 (ru) 2009-02-27
CN101068806A (zh) 2007-11-07
EP1818329A1 (en) 2007-08-15
US7858615B2 (en) 2010-12-28
NO20072382L (no) 2007-08-23
EA200701156A1 (ru) 2007-10-26
CY1112406T1 (el) 2015-12-09
CA2589237C (en) 2013-05-14
TWI354670B (en) 2011-12-21
JPWO2006057397A1 (ja) 2008-06-05
TW200630359A (en) 2006-09-01
NO339021B1 (no) 2016-11-07
MX2007006322A (es) 2007-06-19
CA2589237A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
CY1112406T1 (el) Διενυδρη υδροχλωρικη (s)-(-)-1-(4-φθοροϊσοκινολιν-5-υλ)σουλφονυλ-2-μεθυλ-1,4-ομοπιπεραζινη
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
TW200505919A (en) DPP-IV inhibitors
MX2007006630A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas.
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MY142799A (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
GB0412769D0 (en) Organic compounds
TNSN05244A1 (en) Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
DK1756052T3 (da) Forbedret fremgangsmåde til at fremstille 3-hydroxy-4-hydroxymethyl-pyrrolidin-forbindelser
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
EP1794120A4 (en) peptidase
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
MXPA05010020A (es) Derivados de oxamida.
TW200609228A (en) Substituted n-acyl-2-aminothiazoles
GB0417063D0 (en) Process for the preparation of optically-active compounds
GB0314299D0 (en) Chemical compounds
TW200519071A (en) 3-aryl-2-cyano-3-hydroxy-acrylic acid derivatives
UA93030C2 (ru) Способ получения клопидогрела (варианты) и промежуточные соединения
MXPA05007528A (es) Procedimiento de preparacion de (1s, 4r) 1-acetoxi-4-hidroxiciclopent-2-eno enriquecido enantiomericamente.
DE50206142D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen